AD-35 is a neuroprotectant for treating Alzheimer’s diseases by significantly inhibiting the production and release of proinflammatory cytokines TNF-α and IL-1β.
AD2765, also known as AD 2845 and Sphingosylphosphoryl choline, is a novel thiourea derivative of sphingomyelin that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death.
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration a
AD57, as polypharmacological cancer therapeutic, is designed to regulate multiple targets related to cancer blocks the receptor tyrosine kinase RET in Drosophila (IC50: 2 nM). AD57 effectively suppresses tyrosine kinase RET, weakens the activity of numero
Multitarget AD inhibitor-1 is a reversible and selective inhibitor of butyrylcholinesterase (BuChE) with IC50 values of 7.22 μM and 1.55 μM for human BuChE (hBuChE) and equine serum BuChE (eqBuChE), respectively. Additionally, it exhibits inhibitory activity towards β-secretase (IC50 value of 41.60 μM), amyloid β aggregation (IC50 value of 3.09 μM), and tau aggregation. As a diphenylpropylamine derivative, Multitarget AD inhibitor-1 holds promise for research pertaining to the multifunctional, disease-modifying treatment of Alzheimer's disease.
N-Trifluoroacetyladriamycin is a metabolite of Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar). Valrubicin is a chemotherapy drug utilized to treat bladder cancer. Valrubicin is the anthracycline doxorubicin analog and is administ